Chlorpromazine-Induced Neurological Symptoms Mimicking Stroke in an Elderly Patient with Intractable Hiccups: A Case Report
Article Sidebar
Main Article Content
Abstract
Background: Chlorpromazine, a widely utilized antipsychotic medication, has been recognized for its efficacy in treating intractable hiccups through its antagonistic action on histamine H1, dopamine D2, and muscarinic M1 receptors. Despite its therapeutic benefits, there is a spectrum of potential side effects, including neurological symptoms such as drug-induced stuttering, which poses diagnostic challenges and may lead to unnecessary investigations.
Objective: This case study aims to explore the paradoxical effect of chlorpromazine, which, while effectively treating an 80-year-old male patient's intractable hiccups, induced slurred speech and drowsiness, symptoms that resolved upon cessation of the drug.
Methods: A comprehensive evaluation was conducted, involving the patient's clinical presentation, treatment regimen, and the temporal relationship between medication administration and symptom onset. Investigations included a complete blood count, C-reactive protein, liver function tests, COVID-19 antigen test, cardiac workup, and brain MRI. Treatment response and side effects were meticulously documented, with follow-up to assess the resolution of symptoms.
Results: Following the administration of chlorpromazine (50mg orally), the patient's hiccups ceased, but he subsequently developed slurred speech and drowsiness. These symptoms were not present upon initial examination and resolved completely following the discontinuation of chlorpromazine. The brain MRI conducted to explore potential neurological causes was found to be insignificant, reinforcing the diagnosis of drug-induced neurological symptoms.
Conclusion: While chlorpromazine remains a valuable treatment for intractable hiccups, healthcare providers must be vigilant about its potential to induce neurological symptoms. This case highlights the importance of recognizing drug-induced side effects to avoid unnecessary diagnostic procedures and emphasizes the need for ongoing research into the mechanisms underlying such adverse reactions.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
References:
The Stuttering Foundation: https://www.stutteringhelp.org/
Andrew1. Stuttering Foundation [Internet]. [cited 2024 Feb 26]. Available from: https://www.stutteringhelp.org/
Andrews G, Craig A, Feyer A, Hoddinott S, Howie P, Neilson M. Stuttering: a review of research findings and theories circa 1982. J Speech Hear Disord. 1983;48:226-46.
Aras S. Communication Disorders. In: Gulec C, Koroglu E, editors. Foundations of Psychiatry. 2nd ed. Ankara: Physicians’ Publishing Union; 2007. p. 777-97.
Belgin E, Derinsu U. Incidence of speech and voice disorders in primary school children. In: Proceedings of the 19th National Turkish Congress of Otorhinolaryngology; 1990; Istanbul. p. 158-60.
Mazzucchi A, Moretti G, Carpeggiani P, Parma M. Clinical observations on acquired stuttering. Br J Disord Commun. 1981;16:1.
Blood GW. Laterality differences in child stutterers: heterogeneity, severity levels, and statistical treatments. J Speech Hear Disord. 1985;50:66-72.
Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering, and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry. 1999;66:776-78.
Darby JK, editor. The interaction between speech and disease. In: Speech Evaluation in Medicine. New York: Grune and Stratton; 1981.
Gottschalk LA. Effects of certain benzodiazepine derivatives on disorganization of thought as manifested in speech. Curr Ther Res. 1977;21:192-201.
Shatzberg AF, Cole JO, Blumer DP. Speech Blockage: A tricyclic side effect. Am J Psychiatry. 1978;135(5):600-1.
Saunders M. Dysarthria with tricyclic antidepressants. Br Med J. 1977 Jul 30;317.
Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport. 1997;8:767-70.
Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry. 1999;66:776-78.
Nikvarzn N, Sabouris S. Drug-induced stuttering: A comprehensive literature review. World J Psychiatry. 2022;12(2):236-63.
Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res. 2015;59(1):11-25.
Lesperance B, Schulz V, Hume A. Management of hiccups in the palliative care population: a review. J Palliat Med. 2009 Mar;12(3):243-7. doi: 10.1089/jpm.2008.0193.
Adler L, Leong S, Delgato R. Drug-induced stuttering treated with propanolol. J Clin Psychopharmacol. 1987;7(2):115-6.
Somasetia DH, Sutanto MA, Andriyani FM, Peryoga SU, Hakim DDL. Multi-drugs Abuse Co-ingested with Fake Methanol Beverages in the Indonesian Adolescent: A Case Report. J Drug Alcohol Res. 2021;10(1).
Nwokike MO, Ghasi SI, Ogbonna AO, Ezenwaeze MN, Ezinwa AC. Extrapyramidal Symptoms and Novel Antipsychotic Drugs. Int Neuropsychiatr Dis J. 2022;17(4):1-7.
Motwani S, Murlimanohar K, Karia S, Shah N, Desousa A. Psychogenic Grunting: A Case Report. Indian J Priv Psychiatry. 2020;14(1):41-42.
s G, Craig A, Feyer A, Hoddinott S, Howie P, Neilson M. Stuttering: a review of research findings and theories circa 1982. J Speech Hear Disord 1983; 48:226-246.
Aras S. Communication Disorders: In Gulec C, Koroglu E (editors). Foundations of Psychiatry. Second ed., Ankara: Physicians’ Publishing Union, 2007, 777-797.
Belgin E, Derinsu U. Incidence of speech and voice disorders in primary school children. 19. National Turkish Congress of Otorhinolaryngology. Istanbul, 1990, 158-160.
Mazzucchi, A., Moretti, G., Carpeggiani, P., and Parma, M. Clinical observations on acquired stuttering. British Journal of Disorders of Communication, 1981, 16, 1.
Blood GW. Laterality differences in child stutterers: heterogeneity, severity levels, and statistical treatments. J Speech Hear Disord 1985; 50:66-72.
Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry 1999; 66:776-778.
Darby, J.K. The interaction between speech and disease. In: Speech Evalaation in Medicine, J.K. Darby (ed.). New York: Grune and Stratton, 1981.
Gottschalk, L.A. Effects of certain benzodiazepine derivatives on disorganization of thought as manifested in speech. Current Therapeutic Research, 1977. 21. 192-201.
Shatzberg, A.F.. Cole, J.O., and Blumer, D.P. Speech Blockage: A tricyclic side effect. American Journal ofpsychiatry, 1978, 13.5, 5, 600-601,
Saunders, M. Dysarthria with tricyclic antidepressants. British Medical Journal, July 30, 1977, 317.
Wu JC, Maguire G, Riley G, Lee A, Keator D, Tang C, Fallon J, Najafi A. Increased dopamine activity associated with stuttering. Neuroreport 1997; 8:767-770.
Anderson JM, Hughes JD, Rothi LJ, Crucian GP, Heilman KM. Developmental stuttering and Parkinson’s disease: the effects of levodopa treatment. J Neurol Neurosurg Psychiatry 1999; 66:776-778.
Nikvarzn N, Sabouris S. Drug - induced stuttering: A comprehensive literature review. World J Psychiatry.2022;12(2):236-263
Deb S, Unwin G, Deb T. Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. J Intellect Disabil Res.2015;59(1):11-25
Lesperance B, Schulz V, Hume A. Management of hiccups in the palliative care population: a review. J Palliat Med. 2009 Mar;12(3):243-7. doi: 10.1089/jpm.2008.0193. PMID: 19284276.
Adler L, Leong S, Delgato R. Drug-induced stuttering treated with propanolol. J Clin Psychopharmacol 1987;7(2):115-6.
Somasetia DH, Sutanto MA, Andriyani FM, Peryoga SU, Hakim DDL. Multi-drugs Abuse Co-ingested with Fake Methanol Beverages in the Indonesian Adolescent: A Case Report. J Drug Alcohol Res. 2021;10(1):236130.
Nwokike MO, Ghasi SI, Ogbonna AO, Ezenwaeze MN, Ezinwa AC. Extrapyramidal Symptoms and Novel Antipsychotic Drugs. Int Neuropsychiatr Dis J. 2022;17(4):1-7. PMID: 101632319.
Motwani S, Murlimanohar K, Karia S, Shah N, Desousa A. Psychogenic Grunting: A Case Report. Indian J Priv Psychiatry. 2020;14(1):41-42.